- Release Date: 29/06/15 09:38
- Summary: GENERAL: PEB: Compensation letters sent to Shareholders
- Price Sensitive: No
- Download Document 4.31KB
PEB 29/06/2015 09:38 GENERAL NOT PRICE SENSITIVE REL: 0938 HRS Pacific Edge Limited GENERAL: PEB: Compensation letters sent to Shareholders 29 June 2015 Compensation letters sent to Shareholders On 25th May 2015, Pacific Edge Limited (NZX:PEB) announced that it had reached a settlement with the Financial Markets Authority under which PEB agreed to pay compensation to shareholders who sold PEB shares during certain periods. The detail of the relevant periods is set out in the settlement deed between FMA and PEB, which can be found here: http://www.pacificedge.co.nz/news-and-media/news/pacific-edge-agrees-settleme nt-with-fma-on-continuous-disclosure/ PEB advises that it has today sent letters to shareholders who PEB believes sold shares during the relevant periods and who, therefore, may be entitled to compensation. Shareholders who are entitled to compensation must claim it by 5pm on 24th July 2015. Under the settlement reached with FMA, PEB had the option of offering PEB shares as an alternative form of compensation. PEB has decided not to do so. Accordingly, compensation will be paid in cash and not in PEB shares. If you believe you are entitled to compensation and do not receive a compensation letter, or if you are a broker with a client who sold PEB shares during the relevant periods and your client does not receive a compensation letter, please contact PEB's share registrar LINK Market Services urgently with evidence of your (or your client's) PEB share sales during the relevant periods. LINK Market Services may be contacted at: [email protected] ENDS For more information contact: David Darling Chief Executive Officer Pacific Edge Ltd P: +64 (3) 479 5800 ABOUT Cxbladder Triage Cxbladder Triage is a novel molecular test that combines the power of the genomic biomarkers with extra phenotypic and clinical risk factors to accurately identify and remove patients with hematuria who have a low probability of bladder cancer, from needing to have a full-urological work-up. This is a tool for use by clinicians and physicians in the primary evaluation and is intended to reduce of the number of patients needing an expensive and invasive work-up for urothelial cancer. www.cxbladder.com ABOUT Cxbladder Detect Cxbladder Detect is a proprietary, accurate molecular diagnostic test that enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of urine. Cxbladder Detect is commercially available in New Zealand, Australia and the USA. Cxbladder Detect is available in the USA and NZ as a Laboratory Developed Test (LDT) from the company's CLIA certified laboratories, providing physicians and clinicians with a quick, cost effective and accurate measure of the presence of the cancer, and provides urologists with an effective adjunct to cystoscopy. The Cxbladder Detect cancer detection test has been validated by a multi-centre, international clinical study. www.cxbladder.com ABOUT Bladder Cancer Globally, bladder cancer has the 9th highest incidence and the 4th highest incidence for men. One of the early symptoms of bladder cancer is the presence of blood in the urine, haematuria. People with haematuria often present to their general practitioner before being referred on to a urologist. Bladder cancer has a very high recurrence rate of approximately 50%-70% with up to 30% of these recurring as later stage tumours. However, bladder cancers are highly treatable, especially if detected in the early stages when there is a much higher probability of survival. Timely detection and regular surveillance and monitoring of this cancer is a key element of the clinical process and of the individual's annual healthcare plan. ABOUT Pacific Edge Pacific Edge Limited (NZX: PEB) is a New Zealand based cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic technology for the early detection and monitoring of cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests. It's first commercial product, Cxbladder Detect, is now being actively marketed to physicians and clinicians in New Zealand, Australia, and the USA through the company's wholly owned subsidiaries and selected commercial partners. www.pacificedge.co.nz www.pacificedgedx.com End CA:00266286 For:PEB Type:GENERAL Time:2015-06-29 09:38:22
Add to My Watchlist
What is My Watchlist?
